Clinical trials: Overactive Bladder (OAB)
Overactive Bladder (OAB)
Drug Use Investigation for Toviaz
The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.
- Trial name
- NCT01936870
- Testing
- Fesoterodine (Toviaz)
- Volunteers
- 2,521 people
- Sponsor
- Pfizer
Overactive Bladder (OAB)
Detrol LA In Men With Overactive Bladder.
An interventional active/placebo double blinded parallel randomized controlled study in which at 12 weeks of treatment, the primary endpoint of patient perception of bladder condition is measured along with associated safety and…
- Trial name
- NCT00282932
- Testing
- Detrol LA
- Where
- 81 sites in United States, Canada and 13 more
- Volunteers
- 600 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Overactive Bladder (OAB)
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
The purpose of this study is to observe and describe treatment patterns, like Overactive Bladder (OAB) treatment discontinuation, switching to other therapies and persistence of OAB therapies in routine clinical practice.
- Trial name
- NCT03572231
- Testing
- mirabegron, solifenacin, darifenacin
- Where
- 15 sites in South Korea, Taiwan
- Volunteers
- 805 people
- Sponsor
- Astellas Pharma Singapore Pte. Ltd.
Overactive Bladder (OAB)
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
The purpose of this study was to assess tolerability of mirabegron compared to tolterodine ER in the treatment of participants with symptoms of Overactive Bladder (OAB) as well as the impact of treatment on micturition frequency…
- Trial name
- PREFER (NCT02138747)
- Testing
- Mirabegron, Tolterodine ER
- Where
- 30 sites in United States, Canada
- Volunteers
- 376 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Overactive Bladder (OAB)
A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
The purpose of this study is to track changes in overactive bladder (OAB) medical regimen and/or OAB medication dosage requirements.
- Trial name
- NCT01317810
- Sponsor
- Astellas Pharma Inc
Lower Urinary Tract Symptoms (LUTS), Overactive Bladder (OAB)
Vesitirim™ in Men Postmarketing Observational Study
This is an observational study which will look at the improvement in Lower Urinary Tract Symptoms (LUTS) in Irish men being treated with Vesitirim™ (solifenacin).
- Trial name
- VIM (NCT01639794)
- Testing
- Vesitirim™ (Solifenacin)
- Where
- 5 sites in Ireland
- Volunteers
- 12 people
- Sponsor
- Astellas Pharma Europe Ltd.
Overactive Bladder (OAB) With Symptoms of Frequency, Urgency, and Urgency
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
This Is A Study Of Bioavailability And Food Effect For Fesoterodine.
- Trial name
- NCT01286454
- Testing
- fesoterodine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer
Overactive Bladder (OAB)
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
The study will examine which dose of SVT-40776 is best in terms of efficacy, safety and tolerability compared to placebo and tolterodine
- Trial name
- NCT00507169
- Testing
- SVT-40776
- Sponsor
- Salvat
Overactive Bladder (OAB)
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
To investigate the efficacy and safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT00742833
- Testing
- KUC-7483
- Where
- 6 sites in Japan
- Volunteers
- 400 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Overactive Bladder (OAB)
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
This study will evaluate safety, efficacy and patient's perception of outcome after treatment with darifenacin (7.5 mg once daily (o.d.) with voluntary increase up to 15 mg o.d.) in patients with OAB who are dissatisfied with…
- Trial name
- NCT00366002
- Testing
- Darifenacin
- Where
- 82 sites in United States
- Volunteers
- 500 people
- Sponsor
- Novartis